Pyrazolopyridine derivatives, therapeutic compositions comprising same, and process thereof
申请人:KYORIN SEIYAKU KABUSHIKI KAISHA
公开号:EP0121197A1
公开(公告)日:1984-10-10
Compounds of formula
wherein, R is alkyl or alkoxy, A is tetrahydro- 3-pyridyl which may be substituted at the N-position by alkyl optionally substituted by a hydroxy or alkoxy group, or R'-NHCO- (wherein R1 is a hydrogen, alkyl or unsubstituted or substituted phenyl group) or3-pyridyl group], which possess inhibitory activities on platelet aggregation, and methods for their production as well as therapeutic compositions containing these compounds as used in cerebral and peripheral vascular insufficiency and its complications.
AWANO KATSUYA; SUZUE SEIGO; SEGAWA MITSURU, CHEM. AND PHARM. BULL., 34,(1986) N 7, 2828-2832
作者:AWANO KATSUYA、 SUZUE SEIGO、 SEGAWA MITSURU
DOI:——
日期:——
US4559402A
申请人:——
公开号:US4559402A
公开(公告)日:1985-12-17
Synthesis of 3-substituted pyrazolo(1,5-a)pyridine derivatives with inhibitory activity on platelet aggregation. I.
作者:KATSUYA AWANO、SEIGO SUZUE、MITSURU SEGAWA
DOI:10.1248/cpb.34.2828
日期:——
3-Nicotinoylpyrazolo[1, 5-a]pyridines were synthesized by the raation of 3-unsubstituted pyrazolo[1, 5-a]pyridines with nicotinoyl chloride hydrochloride. Tetrahydronicotinoyl derivatives were obtained by hydrogenation of the nicotinoyl derivatives. Furthermore, N-substituted derivatives were synthesized by the reaction of the tetrahydronicotinoyl derivatives with alkylating regents or isocyanates. These pyrazolo[1, 5-a]pyridines were tested for inhibitory activity on arachidonic acid induced platelet aggregation in vitro and ex vivo. Some of these compounds showed higher inhibitory activity than aspirin. Among them, 2-methyl-3-(1, 4, 5, 6-tetrahydronicotinoyl)pyrazolo[1, 5-a]pyridine was found to be the most active compound.